化合物 T16085
化合物 T16085 性质
| 熔点 | 122 °C |
|---|---|
| 沸点 | 735.5±60.0 °C(Predicted) |
| 密度 | 1.36±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：250 mg/mL（568.82 mM） |
| 形态 | 固体 |
| 酸度系数(pKa) | 4.19±0.10(Predicted) |
| 颜色 | 白色至米白色 |
化合物 T16085 用途与合成方法
|
αvβ1 1.6 nM (IC 50 , inhibition of fibronectin-binding ) |
αvβ3 2.8 nM (IC 50 , inhibition of vitronectin-binding) |
αvβ5 0.1 nM (IC 50 , inhibition of vitronectin-binding) |
αvβ6 0.7 nM (IC 50 , inhibition of LAP-binding) |
αvβ8 0.5 nM (IC 50 , inhibition of LAP-binding) |
α5β1 12.2 nM (IC 50 , inhibition of fibronectin-binding) |
MK-0429 (100 or 300 mg/kg, p.o., twice daily b.i.d., 2 weeks) reduces metastatic tumor colony formation and area in the lungs. MK-0429 is safe and efficacious in significantly decreasing melanoma metastasis in the lungs.
| Animal Model: | B6D2F1 hybrid female mice |
| Dosage: | 100 or 300 mg/kg |
| Administration: | P.o., twice daily (b.i.d.), 2 weeks |
| Result: | MK-0429 at 100 and 300 mg/kg reduced the number of metastatic tumor colonies by 64 and 57%, respectively, and the high dose also reduced the tumor area by 60% as compared to the vehicle [2] . |
化合物 T16085 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-15102 | 1 mg | 2045 | ||
| 2024-04-30 | HY-15102 | 化合物 T16085 | 227963-15-7 | 5mg | 4500 |
